Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 214

Results For "TN"

2444 News Found

Asian Development Bank to loan US $ 300 mn to improve India’s primary healthcare
Public Health | November 24, 2021

Asian Development Bank to loan US $ 300 mn to improve India’s primary healthcare

The programme will be implemented across 13 states and benefit 256 min


Obseva announces U.S. FDA acceptance of new drug application for linzagolix
Biotech | November 23, 2021

Obseva announces U.S. FDA acceptance of new drug application for linzagolix

Obseva announced previously that the company has entered into a partnership with Syneos Health to support commercialization of linzagolix in the US and EU


U.S. FDA approves Alembic’s Formoterol Fumarate inhalation solution
Drug Approval | November 23, 2021

U.S. FDA approves Alembic’s Formoterol Fumarate inhalation solution

The ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies


Indian pharma CEOs bet big on innovation to achieve US $130 bn
News | November 23, 2021

Indian pharma CEOs bet big on innovation to achieve US $130 bn

While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation


AstraZeneca opens Discovery Centre in Cambridge
Biotech | November 23, 2021

AstraZeneca opens Discovery Centre in Cambridge

State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem


Molbio has pioneered point of care molecular testing: Sriram Natarajan
interviews | November 22, 2021

Molbio has pioneered point of care molecular testing: Sriram Natarajan

Molbio Diagnostics has been the pioneer in providing access to molecular testing through its Truenat Real Time PCR platform. Sriram Natarajan, Director & CEO, of the company shares his experiences on the journey so far in an interview with Thomas C Thottathil


CStone and Jiangsu Hengrui sign exclusive licensing agreement for cancer drugs in China
Biotech | November 22, 2021

CStone and Jiangsu Hengrui sign exclusive licensing agreement for cancer drugs in China

CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region


Merck showcases potential for several cancers, MS and lupus
News | November 22, 2021

Merck showcases potential for several cancers, MS and lupus

Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline


Funding push to pharma R&D critical for unleashing next phase of growth
News | November 20, 2021

Funding push to pharma R&D critical for unleashing next phase of growth

The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation


Laurus Labs acquires stake in IIT Bombay incubated ImmunoACT
News | November 20, 2021

Laurus Labs acquires stake in IIT Bombay incubated ImmunoACT

ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.